| GLP-1 RAs (n = 2390) | Non-GLP-1 RAs (n = 11,729) | Standardized difference, %a |
---|---|---|---|
Matched variables | |||
 Age at diabetes diagnosis (years) | 52.65 (10.38) | 53.30 (10.37) | 6.29 |
 Sex, n (%) |  |  | 0.82 |
  Men | 1315 (55.02) | 6501 (55.43) |  |
  Women | 1075 (44.98) | 5228 (44.57) |  |
 Duration of diabetes (years) | 4.22 (2.82) | 4.18 (2.76) | 1.31 |
 Average daily dose before cohort entry | |||
  Metformin (DDD) | 0.555 (0.296) | 0.530 (0.293) | 8.45 |
  Sulfonylureas (DDD) | 0.0537 (0.143) | 0.0442 (0.124) | 7.08 |
Unmatched variables | |||
 Educational level, n (%) |  |  | 13.75 |
  <10 years | 481 (20.12) | 2961 (25.25) |  |
  10–12 years | 1236 (51.72) | 5438 (46.36) |  |
  >12 years | 673 (28.16) | 3330 (28.39) |  |
 Country of birth, n (%) |  |  | 30.62 |
  Sweden | 1980 (82.85) | 8210 (70.00) |  |
  Abroad | 410 (17.15) | 3519 (30.00) |  |
 Medical history |  |  |  |
  Hypertension | 1908 (79.83) | 8452 (72.06) | 18.26 |
  Cardiovascular diseases | 370 (15.48) | 1741 (14.84) | 1.78 |
  Other retinal disorders | 7 (0.29) | 40 (0.34) | 0.86 |
 Average daily dose after cohort entry | |||
  Metformin (DDD) | 0.629 (0.372) | 0.560 (0.350) | 19.08 |
  Sulfonylureas (DDD) | 0.0741 (0.220) | 0.0831 (0.218) | 4.12 |
  GLP-1 RAs (DDD) | 0.788 (0.228) | - | - |